- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02397239
Comparison of Cost-effectiveness of Continuation Maintenance Therapy With Six Cycles of Pemetrexed Versus Pemetrexed Until Disease Progression for Metastatic Non-squamous Non-small-cell Lung Cancer
Protocol title:
Comparison of cost-effectiveness of continuation maintenance therapy with six cycles of pemetrexed versus pemetrexed until disease progression for metastatic non-squamous non-small-cell lung cancer (NSCLC)
Study design:
An open-labelled, randomized, phase 2 trial
Indication:
Patients with stage IV non-squamous NSCLC, an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, and have received first-line or second-line chemotherapy with pemetrexed plus platinum for 4 cycles
Treatment:
Maintenance pemetrexed 500 mg/m2 every 3 weeks for six cycles versus until disease progression
Objectives:
Primary endpoint:
1. Progression-free survival in the intention-to-treat population
Secondary endpoints:
- Cost-effectiveness
- Overall survival
- Quality-of-life (QoL)
- Quality-adjusted progression-free survival (QA-PFS)
- Quality-adjusted life expectancy (QALE)
- Tumor response rate
- Adverse events
Planned sample size:
36 patients in each arm; total 72 patients
Total number of sites:
1 site
Duration of patient enrollment:
3 years
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
Inclusion criteria:
- Males and females ≥ 20 years of age
- ECOG performance status of 0-1
- Histologically or cytologically verified non-squamous NSCLC
- Stage IV disease, as defined by American Joint Committee on Cancer 7th edition staging, prior to first-line or second-line chemotherapy with pemetrexed plus platinum
- At least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
- Completion of 4 cycles of first-line or second-line chemotherapy with pemetrexed plus platinum and documented radiographic evidence of a complete or partial tumor response or stable disease by RECIST 1.1
Adequate organ function, including followings:
Bone marrow:
Absolute neutrophil count ≥ 1.5 x 103 /μL White blood cell ≥ 3.0 x 103 /μL Platelet count ≥ 75 x 103 /μL Hemoglobin ≥ 8.0 g/dL
Hepatic:
Total bilirubin ≤ 1.5 x upper normal limit (UNL) Aspartate aminotransferase (AST) ≤ 3.0 x UNL (≤ 5.0 x UNL if liver metastasis) Alanine aminotransferase (ALT) ≤ 3.0 x UNL (≤ 5.0 x UNL if liver metastasis)
Renal:
Estimated glomerular filtration rate ≥ 30 mL/min
- Estimated life expectancy of at least 6 months
- Ability to comply with study and follow-up procedures
- Signed informed consent document
Exclusion criteria:
- Squamous cell and/or mixed small-cell, non-small-cell histology
- Prior participation in any investigational drug study within 4 weeks
- Prior malignancy other than NSCLC, except those remain disease-free for ≥ 3 years after curative treatment, non-melanoma skin cancer or in situ cervical cancer
- Serious concomitant systemic disorders, such as acute or recent myocardial infarction (< 6 months before enrollment), congestive heart failure with New York Heart Association functional class II~IV, frequent exacerbations of chronic obstructive pulmonary disease (≥ 2 hospitalizations per year), or recent cerebrovascular disease (< 6 months before enrollment)
- Active uncontrolled infections or HIV infection
- Current or planned pregnancy, or breast feeding in women
- Symptomatic central nervous system metastasis unless the patient has completed successful local therapy and has been off corticosteroids for ≥ 4 weeks
- Concurrent administration of any other antitumor therapy including chemotherapy, target therapy, immunotherapy, and hormone therapy
- Psychiatric disorders that would compromise the patient's compliance or decision
Criteria for evaluation:
QoL:
QoL will be measured using the EuroQol 5-dimensional questionnaire (EQ-5D), World Health Organization Quality-of-Life, brief version (WHOQOL-BREF), European Organization for Research and Treatment of Cancer (EORTC) questionnaires.
Efficacy:
Tumor response rate will be determined by RECIST 1.1. Data of progression-free survival and overall survival will be collected for all subjects.
QA-PFS and QALE:
Investigators will adjust the progression-free survival by the utility values of QoL measured from the EQ-5D to obtain the QA-PFS. In addition, investigators will extrapolate the survival function to lifetime based on the survival ratios between patients and age- and sex-matched referents simulated from the life tables of Taiwan. After adjusting the lifetime survival by the utility values of QoL, the QALE will also be estimated using quality-adjusted life-year (QALY) as the unit.
Cost-effectiveness:
The monthly healthcare expenditures, which included National Health Insurance-reimbursed and out-of-pocket direct medical costs, will be obtained from the reimbursement database of National Cheng Kung University Hospital. These values were multiplied by the corresponding survival probabilities to calculate the lifetime costs or costs during the progression-free period. Hence, costs/life-year or costs/QALY can be obtained for comparison of cost-effectiveness.
Adverse events:
Safety parameters include laboratory adverse events (e.g., anemia, leukopenia, neutropenia, thrombocytopenia, creatinine, AST, ALT) and non-laboratory adverse events (e.g., fatigue, nausea, vomiting, mucositis/stomatitis, anorexia, diarrhea, constipation, infection, febrile neutropenia, pain, sensory neuropathy, rash, edema, watery eye). Common Terminology Criteria for Adverse Events (CTCAE) v4.0 will be used to grade toxicities.
Studientyp
Einschreibung (Voraussichtlich)
Kontakte und Standorte
Studienorte
-
-
-
Tainan, Taiwan, 704
- Rekrutierung
- National Cheng Kung University Hospital
-
Kontakt:
- Szu-Chun Yang, M.D.
- Telefonnummer: +886 972402279
- E-Mail: yangszuchun@gmail.com
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Males and females ≥ 20 years of age
- ECOG performance status of 0-1
- Histologically or cytologically verified non-squamous NSCLC
- Stage IV disease, as defined by American Joint Committee on Cancer 7th edition staging, prior to first-line or second-line chemotherapy with pemetrexed plus platinum
- At least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
- Completion of 4 cycles of first-line or second-line chemotherapy with pemetrexed plus platinum and documented radiographic evidence of a complete or partial tumor response or stable disease by RECIST 1.1
Adequate organ function, including followings:
Bone marrow:
Absolute neutrophil count ≥ 1.5 x 103 /μL White blood cell ≥ 3.0 x 103 /μL Platelet count ≥ 75 x 103 /μL Hemoglobin ≥ 8.0 g/dL
Hepatic:
Total bilirubin ≤ 1.5 x upper normal limit (UNL) Aspartate aminotransferase (AST) ≤ 3.0 x UNL (≤ 5.0 x UNL if liver metastasis) Alanine aminotransferase (ALT) ≤ 3.0 x UNL (≤ 5.0 x UNL if liver metastasis)
Renal:
Estimated glomerular filtration rate ≥ 30 mL/min
- Estimated life expectancy of at least 6 months
- Ability to comply with study and follow-up procedures
- Signed informed consent document
Exclusion Criteria:
- Squamous cell and/or mixed small-cell, non-small-cell histology
- Prior participation in any investigational drug study within 4 weeks
- Prior malignancy other than NSCLC, except those remain disease-free for ≥ 3 years after curative treatment, non-melanoma skin cancer or in situ cervical cancer
- Serious concomitant systemic disorders, such as acute or recent myocardial infarction (< 6 months before enrollment), congestive heart failure with New York Heart Association functional class II~IV, frequent exacerbations of chronic obstructive pulmonary disease (≥ 2 hospitalizations per year), or recent cerebrovascular disease (< 6 months before enrollment)
- Active uncontrolled infections or HIV infection
- Current or planned pregnancy, or breast feeding in women
- Symptomatic central nervous system metastasis unless the patient has completed successful local therapy and has been off corticosteroids for ≥ 4 weeks
- Concurrent administration of any other antitumor therapy including chemotherapy, target therapy, immunotherapy, and hormone therapy
- Psychiatric disorders that would compromise the patient's compliance or decision
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: Kohorte
- Zeitperspektiven: Interessent
Kohorten und Interventionen
Gruppe / Kohorte |
---|
Six cycles
Maintenance pemetrexed 500 mg/m2 every 3 weeks for six cycles
|
Until disease progression
Maintenance pemetrexed 500 mg/m2 every 3 weeks until disease progression
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Progressionsfreies Überleben
Zeitfenster: 1 Jahr
|
1 Jahr
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Gesamtüberleben
Zeitfenster: 1 Jahr
|
1 Jahr
|
|
Cost-effectiveness: Cost/QA-PFS
Zeitfenster: 2 years
|
Quality-adjusted progression-free survival (QA-PFS)
|
2 years
|
Quality-of-life (QoL) Questionnaire
Zeitfenster: 1 year
|
1 year
|
|
Quality-adjusted progression-free survival (QA-PFS)
Zeitfenster: 1 year
|
1 year
|
|
Quality-adjusted life expectancy (QALE)
Zeitfenster: 1 year
|
1 year
|
|
Ansprechrate des Tumors
Zeitfenster: 1 Jahr
|
1 Jahr
|
|
Number of Adverse events
Zeitfenster: 1 year
|
1 year
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Voraussichtlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- A-BR-103-062
- MOHW103-TD-B-111-06 (Andere Zuschuss-/Finanzierungsnummer: The Ministry of Health and Welfare, Taiwan)
- MOHW103-TDU-B-211-113002 (The Ministry of Health and Welfare, Taiwan)
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Nicht-kleinzelligem Lungenkrebs
-
National Cancer Institute (NCI)AbgeschlossenAIDS-bedingtes peripheres/systemisches Lymphom | AIDS-assoziiertes diffuses großzelliges Lymphom | AIDS-bedingtes diffuses gemischtzelliges Lymphom | AIDS-bedingtes kleines Noncleaved-Cell-LymphomVereinigte Staaten
-
National Cancer Institute (NCI)AbgeschlossenAIDS-bedingtes peripheres/systemisches Lymphom | AIDS-assoziiertes diffuses großzelliges Lymphom | AIDS-bedingtes immunoblastisches großzelliges Lymphom | AIDS-bedingtes kleines Noncleaved-Cell-LymphomVereinigte Staaten
-
Jason Robert GotlibNovartis; Novartis PharmaceuticalsAbgeschlossenSystemische Mastozytose, aggressiv (ASM) | Leukämie, Mastzelle | Hämatologische Non-Mast Cell Lineage Disease (AHNMD)Vereinigte Staaten
-
Adelphi Values LLCBlueprint Medicines CorporationAbgeschlossenMastzellleukämie (MCL) | Aggressive systemische Mastozytose (ASM) | SM w Assoc Clonal Hema Non-Mast Cell Lineage Disease (SM-AHNMD) | Schwelende systemische Mastozytose (SSM) | Indolente systemische Mastozytose (ISM) ISM-Untergruppe vollständig rekrutiertVereinigte Staaten
-
Children's Oncology GroupNational Cancer Institute (NCI)AbgeschlossenDiffuses großzelliges Lymphom im Kindesalter | Immunoblastisches großzelliges Lymphom im Kindesalter | Burkitt-Lymphom im Kindesalter | Unbehandelte akute lymphoblastische Leukämie im Kindesalter | Stadium I des großzelligen Lymphoms im Kindesalter | Stadium I des kleinen, nicht gespaltenen... und andere BedingungenVereinigte Staaten
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI); Genentech, Inc.RekrutierungDiffuses großzelliges B-Zell-Lymphom | Wiederkehrendes diffuses großzelliges B-Zell-Lymphom | Refraktäres diffuses großzelliges B-Zell-Lymphom | Primäres mediastinales (thymisches) großes B-Zell-Lymphom | Follikuläres Lymphom Grad 3b | Transformierte follikuläre Lymphe zu Diff Large B-Zell-Lymphom und andere BedingungenVereinigte Staaten
-
Mitchell CairoRekrutierungHodgkin-Lymphom | Sichelzellenanämie | Akute Leukämie | Beta-Thalassämie | Non-Hodgkin-Lymphom | Schwere aplastische Anämie | Diamond-Blackfan-Anämie | Amegakaryozytäre Thrombozytopenie | KostmannVereinigte Staaten
-
National Cancer Institute (NCI)BeendetLymphoproliferative Störung nach der Transplantation | Rezidivierendes großzelliges Lymphom im Kindesalter | Rezidivierendes kindliches lymphoblastisches Lymphom | Rezidivierendes kleinzelliges Lymphom im Kindesalter | Rezidivierendes/refraktäres Hodgkin-Lymphom im Kindesalter | AIDS-bedingtes... und andere BedingungenVereinigte Staaten
-
National Cancer Institute (NCI)Aktiv, nicht rekrutierendWeichteilsarkom | Osteosarkom | Ewing-Sarkom | Bösartiges Gliom | Ependymom | Rhabdoider Tumor | Fortgeschrittenes bösartiges solides Neoplasma | Refraktärer bösartiger fester Neoplasma | Rhabdomyosarkom | Rezidivierende bösartige solide Neubildung | Rezidivierendes Neuroblastom | Refraktäres Neuroblastom | Refraktäres... und andere BedingungenVereinigte Staaten, Puerto Rico
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); University of Arkansas; The Emmes Company, LLCAbgeschlossenAIDS-bedingtes peripheres/systemisches Lymphom | AIDS-assoziiertes diffuses großzelliges Lymphom | AIDS-bedingtes diffuses gemischtzelliges Lymphom | AIDS-bedingtes diffuses kleinzelliges Lymphom | AIDS-bedingtes immunoblastisches großzelliges Lymphom | AIDS-assoziiertes lymphoblastisches... und andere BedingungenZimbabwe, Kenia